• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»active pharmaceutical ingredients

How CordenPharma’s AmbioPharm deal strengthens U.S. and China peptide API supply

By Pallavi Madhiraju on May 27, 2026   Pharma & Biotech  

How CordenPharma’s AmbioPharm deal strengthens U.S. and China peptide API supply

Find out how CordenPharma’s AmbioPharm deal expands peptide API capacity and reshapes global CDMO competition.

Could Eli Lilly’s $4.5bn Indiana investment widen its lead in obesity and advanced therapies?

By Pallavi Madhiraju on May 9, 2026   Pharma & Biotech  

Could Eli Lilly’s $4.5bn Indiana investment widen its lead in obesity and advanced therapies?

Obesity drug demand is outrunning pharma capacity. Eli Lilly’s Indiana bet shows manufacturing is now a strategic moat.

Biocatalysis integration deal between SK pharmteco and Prozomix highlights greener pharma production shift

By Soujanya Ravi on March 25, 2026   Pharma & Biotech  

Biocatalysis integration deal between SK pharmteco and Prozomix highlights greener pharma production shift

SK pharmteco partners with Prozomix to expand biocatalysis in drug manufacturing. Discover what this means for greener APIs and global CDMO strategy.

Recent Posts

  • Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?
  • Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity
  • AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
  • Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes